Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

0.00

-0.00 (0.00%)

2 watching

DON'T BUY

Comes into the health care theme that he thinks will be dominate into the next 10 years. Not his favourite way to participate.

DON'T BUY

Boston Scientific (BSX-N) had the majority share in the business, they are a supplier, so why is it weak. Boston is just as weak. The problem with the pharma sector is investors never look at what it is today but what is the marginal change tomorrow, such as competition with a better product.

TRADE

Technology is superior then Boston Scientific, and Boston markets for them. (for their main product). Would rather buy Boston, because it is more diversified, and slightly cheaper.

BUY

Longer term, they're going to have to start filling their pipeline more. Coated stents have been a great success. Distributor, Boston Scientific, have about 70% of the market so far which will generate great cash over the next couple of years. Management is good and should be able to redeploy cash to build up by acquisitions, etc.

TRADE

The coating on the stents seems to be a bit better than the ones from Johnson & Johnson.

DON'T BUY

Fully valued.

WAIT

His technical screening looks for stocks that are forming base patterns. Starting to see that now and starting to get a little bit attractive. Hasn't done anything positive in terms of upside volume, surges or money flow. Once you see that, the story gets really exciting.

BUY

As an emerging technology, the stock got a very high multiple, but once it gets up there, how do you keep that high multiple? Very difficult unless you continue to have new products and excitement. A solid company with a solid product, but doesn't think it will ever get the multiple that it had before. Probably an OK buy today.

DON'T BUY

Had a major sell off and is probably in some what of a support zone. Still below its 200 day moving average.

PAST TOP PICK

(A Top Pick June 23/04. Down 15%.) Had a recall of their stent 2 days later and they dropped market share to 55%, but are now back to 70%. Still buying.

BUY

A good probability that the stock will move higher. Everything is lining up for them to get a higher royalty from Boston Scientific.

PAST TOP PICK

(A Top Pick Aug 17/04. Up 11%.) Their distributor, Boston Scientific, have announced very good results. Market share is back to where it was before the stent recall. Looking to expand their technology in stents.

HOLD

Bullish on this company. Revenue stream from their coated stents is looking quite strong.

DON'T BUY

A very volatile stock. A one product stock.

BUY

Looking at it. Likes the stock. Long term buy.

Showing 46 to 60 of 140 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)